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Abstract
Background: In Brazil, accidents with venomous animals are considered a public health problem. Tityus serrulatus
(Ts), popularly known as the yellow scorpion, is most frequently responsible for the severe accidents in the country.
Ts envenoming can cause several signs and symptoms classified according to their clinical manifestations as mild,
moderate or severe. Furthermore, the victims usually present biochemical alterations, including hyperglycemia.
Nevertheless, Ts envenoming and its induced hyperglycemia were never studied or documented in a patient with
diabetes mellitus (DM). Therefore, this is the first study to evaluate the glycemia during Ts envenoming using a
diabetic animal model (NOD, non-obese diabetic).
Methods: Female mice (BALB/c or NOD) were challenged with a non-lethal dose of Ts venom. Blood glucose level
was measured (tail blood using a glucose meter) over a 24-h period. The total glycosylated hemoglobin (HbA1c) levels
were measured 30 days after Ts venom injection. Moreover, the insulin levels were analyzed at the glycemia peak.
Results: The results demonstrated that the envenomed NOD animals presented a significant increase of glycemia,
glycosylated hemoglobin (HbA1c) and insulin levels compared to the envenomed BALB/c control group, corroborating
that DM victims present great risk of developing severe envenoming. Moreover, the envenomed NOD animals
presented highest risk of death and sequelae.
Conclusions: This study demonstrated that the diabetic victims stung by Ts scorpion should be always considered
a risk group for scorpion envenoming severity.
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Background
In Brazil, accidents involving venomous animals are
considered a public health problem. Tityus serrulatus
(Ts), popularly known as the yellow scorpion, is most
frequently responsible for these accidents. During the
period from 2000 to 2015, 727,113 cases of scorpion
envenoming were reported in Brazil, with 1026 deaths
and a mortality rate of 0.14 % [1–4].
Envenoming by Ts can cause several signs and symptoms
according to not only the content of venom, but also the
victim’s body weight, the blood-brain-barrier permeability,
sex, health conditions and sting location. The mild
envenoming is characterized by an intense local pain and
possible paresthesia. Moderate envenoming manifests
through local pain as well as nausea, sweating, vomiting,
tachycardia, tachypnea and increasing of blood pressure.
Severe envenoming presents the same symptoms of mod-
erate followed by agitation and exhaustion, abdominal
pain, stiffness and muscle spasms, convulsions, fever, dehy-
dration, cardiac arrhythmias, heart failure and even coma
[5–11]. Moreover, biochemical alterations are also ob-
served during Ts envenoming such as hyperglycemia
[6, 12–15].
Hyperglycemia is a sign constantly observed in dia-
betic individuals. Diabetes mellitus (DM) currently
affects about 314 million people worldwide. Solely in
2012, it was responsible for 1.5 million deaths according
to the World Health Organization (WHO). Currently,
based on the etiology of the disease, DM can be
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classified into two types: type 1 and type 2 [16]. Al-
though the pathologies have different origins, both have
similar signs and symptoms such as hyperglycemia, poly-
uria, polyphagia, polydipsia, unexplained weight loss and
may also include foot pain, blurred vision, frequent in-
fections and even coma [17, 18].
The type 1 DM, or insulin-dependent DM, has a gen-
etic etiology with the most common type being among
children and juveniles. It is an autoimmune disease in
which self-reactive T cells induce the B cell production
of specific antibodies against beta cells of the islets of
Langerhans. This autoimmune mechanism results in the
destruction of these cells and consequently the decrease
of insulin production [19, 20]. On the other hand, type 2
DM is the most common type of diabetes (accounts for
90 %). It is considered a chronic metabolic disorder and
has been characterized by impaired insulin action and/or
abnormal insulin secretion and eventual pancreatic beta-
cell failure. An early abnormality in the disease is insulin
resistance, which is the key linking factor for the meta-
bolic syndrome disease cluster of glucose intolerance,
hypertension and dyslipidemia [21–23].
The model employing non-obese diabetic (NOD) ani-
mals is useful for type 1 diabetes, and presents an auto-
immune genetic disease where T cells (CD4+andCD8+)
become self-reactive to pancreatic islets, resulting in in-
flammation during the first 3 to 4 weeks of life. How-
ever, only after mice reach 4 to 6 months of age does it
become possible to verify insulitis, which results in insu-
lin deficiency and therefore the clinical signs of diabetes
[24, 25]. Thus, based on the Ts venom-induced hypergly-
cemia and the high incidence of diabetic patients, this is
the first study to investigate the Ts envenoming com-




The Ts scorpions, collected from the Ribeirão Preto re-
gion, were kept in the Serpentarium of the Medical School
of RibeirãoPreto (FMRP/USP). The venom extraction
from 145 scorpions was performed using the telson elec-
trical stimulation method─ 12 mV [26]. After extraction,
the pooled venom was desiccated and stored at –20 °C.
The use of Ts venom was approved by the Genetic Patri-
mony Management Board (CGEN/MMA), through the
Access and Shipment Component of Genetic Heritage for
scientific research purposes (number 010174/2014-1).
Mass assessment of the venom of T. serrulatus
The desiccated venom was dispersed in 1 mL of ultra-
pure water and centrifuged at 10,015 × g, 4 °C for
10 min, and the supernatant was stored at 4 °C. The pel-
let was resuspended using the same conditions. The total
supernatant (2 mL) resulted in soluble pooled venom
without the presence of mucus.
The mass of soluble pooled venom was estimated by
absorbance readings at 280 nm using the NanoDrop
spectrophotometer 2000 (Thermo Scientific, USA) and






The venom was analyzed using tricine sodium dodecyl
sulfate polyacrylamide gel electrophoresis (Tricine-SDS-
PAGE) according to the method used for ultra-low-mass
proteins [28]. The 16.5 % separating gel used was over-
laid by a 5 % stacking gel. Samples consist of different
masses of Ts venom (10, 20 and 30 μg) and the molecu-
lar mass marker (M-3546, Sigma-Aldrich®, USA). The
gel was stained with Coomassie Blue plus one PhastGel®
R-350 (GE Healthcare, Sweden) and destained with 10 %
acetic acid (V/V).
Animals
Females of BALB/c and NOD lineage (18–25 g) were ob-
tained from the biotherium of the School of Pharmaceut-
ical Sciences of Ribeirão Preto (FCFRP/USP) and the
biotherium of the Ribeirão Preto Medical School (FMRP/
USP), respectively. The animals were kept in cages with
filters in an air-conditioned environment (23 ± 1 °C, 55 ±
5 % humidity) until the blood glucose values of NOD
animals became significantly higher than those of the con-
trols (BALB/c), indicating the hyperglycemia characteristic
of the diabetic state (15 weeks old). Food and water were
provided ad libitum. Mouse experimental models are in
accordance with the Ethical Principles in Animal Experi-
mentation under the license number 13.1.372.53.0.
Basal blood glucose levels and T. serrulatus venom dose
The basal glucose levels of BALB/c and NOD mice were
measured in tail blood using a glucose meter (One
Touch Ultra®, Lifescan, USA). The dose of Ts venom
capable of inducing hyperglycemia in mice (BALB/c and
NOD) was also adjusted. The doses of 1 mg/kg and
0.5 mg/kg were tested in the different mouse species.
Kinetic assay of glucose induced by T. serrulatus venom
Groups of female BALB/c or NOD mice (18–25 g, n = 4)
were challenged with a non-lethal dose of Ts venom
(0.5 mg/kg) using subcutaneous injection (similar to scor-
pion sting site), diluted in sterile physiological solution
(0.9 % W/V of NaCl) in a final volume of 0.2 mL. Control
groups received only sterile physiological solution. Glucose
was measured in tail blood using a glucose meter (One
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Touch Ultra®, Lifescan, USA). Blood glucose was measured
over a 24-h period (at 0, 1, 2, 3, 4, 5, 6, 12 and 24 h).
Glycosylated hemoglobin (HbA1c) induced by
T. serrulatus venom
Groups of female BALB/c or NOD mice (18–25 g, n = 4)
were challenged with a non-lethal dose of Ts venom
(0.5 mg/kg) using subcutaneous injection (similar to
scorpion sting site), diluted in sterile physiological solu-
tion (0.9 % W/V of NaCl) in a final volume of 0.2 mL.
Control groups received only sterile physiological solution.
After 30 days (to reflect mean glycemia for the previous
30 days), 0.5 mL of blood from the retro-orbital cavity
was collected in heparinized tubes under intraperitoneal
anesthesia: ketamine 60 mg/kg (Dopalen, Agripands Brasil
Ltda®, Brazil) and xylazine 8 mg kg (Rompun, Bayer
Animal Health®, Brazil). The blood was centrifuged at
10,000 rpm for ten minutes, at 4 °C, to obtain the
plasma. The measurement of total glycosylated
hemoglobin (HbA1c) levels was performed according to
the manufacturer’s instructions (Doles®, Brazil).
Insulin levels induced by T. serrulatus venom
Groups of female BALB/c or NOD mice (18–25 g, n = 4)
were challenged with a non-lethal dose of Ts venom
(0.5 mg/kg) using subcutaneous injection (similar to scor-
pion sting site), diluted in sterile physiological solution
(0.9 % W/V of NaCl) in a final volume of 0.2 mL. Control
groups received only sterile physiological solution. After
reaching the hyperglycemia peak (1 h after envenom-
ation), 0.5 mL of blood from the retro-orbital cavity was
collected in heparinized tubes under anesthesia. The blood
was centrifuged at 10,000 rpm for 10 min, at 4 °C, to
obtain the plasma. The insulin assay was performed using
the immunoassay method according to the manufacturer’s
instructions (Ultra Sensitive Mouse Insulin ELISA kit,
Crystal Chem, USA).
Results
T. serrulatus venom mass and electrophoresis
The pooled venom obtained from 145 Ts scorpions
resulted in 21 mg of soluble venom, a median of
0.14 mg per scorpion.
The Tricine-SDS-PAGE indicates the Ts venom pro-
tein profile using different masses (10, 20 and 30 μg)
(Fig. 1). Two main bands of low molecular masses were
observed. The sodium-channel toxins (NaTxs; from 60
to 76 amino acid residues) are the main proteins evi-
denced in the electrophoretic band of molecular mass
between 6000 and 8000 Da, whereas the potassium-
channel toxins (KTxs; from 22 to 47 amino acid resi-
dues) are the main components of the electrophoretic
band from 5000 to 4000 Da.
T. serrulatus venom increased the glucose levels of mice
The median basal glucose – time 0, before Ts venom
(TsV) injection – was 82.9 and 125 mg/dL for BALB/c
and NOD mice, respectively (Fig. 2a). Ideally, NOD mice
are considered diabetic with glucose levels higher than
200 mg/dL. However, during the experimental design
standardization using NOD mice, we observed that both
the dose of Ts venom and the glucose basal levels were
limiting factors to the experiment, inducing lethality of
25 to 100 % (Fig. 2b). Therefore, we decided to use
Fig. 1 Electrophoretic profile of the pooled Ts venom. Molecular mass markers (lane 1); pooled Ts venom: 10, 20 and 30 μg (lanes 2, 3 and 4, respectively).
NaTxs: voltage-gated sodium channel toxins. KTxs: voltage-gated potassium channel toxins. Coomassie Blue plus one PhastGel® R-350 staining
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NOD animals presenting glucose levels lower than
150 mg/dL, but significantly higher than glucose levels
of the BALB/c control (p < 0.001) and the Ts venom con-
centration of 0.5 mg/kg (100 % survival).
All mouse groups that received 0.5 mg/kg of Ts venom
showed hyperglycemia 1 h after envenomation, com-
pared to the respective control (Fig. 3). However, the
hyperglycemia was much more impressive in the NOD
group, reaching glucose levels ≥ 200 mg/dL. During the
analyzed time, glucose levels decrease, presenting a sig-
nificant hypoglycemic period at 4 h for BALB/c and at 5
to 6 h for NOD animals. Nevertheless, the basal glucose
levels for all challenged mice were reestablished after
12 h.
Fig. 2 Standardization of basal glucose levels and T. serrulatus venom dose. a Basal glucose (time 0, before TsV injection) was measured in tail
blood extracted from mice using a glucose meter (One Touch Ultra®, Lifescan, USA). Results are expressed as means ± SD (n = 4), which were
analyzed by paired t test (*p < 0.001). b NOD survival using different glucose basal levels (> 200, < 200 and < 150 mg/dL) and T. serrulatus venom
(TsV) concentrations (0.5 and 1 mg/kg)
Fig. 3 Kinetic glucose level assay of BALB/c and NOD mice injected with Ts venom. Groups of mice were injected with 0.5 mg/kg of T. serrulatus
venom (TsV) and glucose levels were measured throughout 24 h. Glucose was measured in mouse tail blood using a glucose meter (One Touch
Ultra®, Lifescan, USA). *p < 0.05 and **p < 0.001 compared to the corresponding control group. Glucose levels were significant different at all
points between control groups (BALB/c control vs NOD control). Data are presented as means ± SD (n = 4), which were analyzed by ANOVA
and Tukey’s multiple comparison test
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T. serrulatus venom affected the glycosylated hemoglobin
(HbA1c) of NOD mice
The total glycosylated hemoglobin (HbA1c) was analyzed
in mouse blood 30 days after envenoming. The results
demonstrate that although Ts venom had induced hyper-
glycemia in BALB/c mice, it was not able to augment
HbA1c (Fig. 4a). However, Ts venom caused a significant
increase of HbA1c in envenomed NOD animals. Further-
more, the NOD group control also presented a significant
increase of HbA1, indicating the diabetic condition of
the mice.
T. serrulatus venom increased insulin levels of NOD mice
The insulin levels were analyzed in mouse plasma during
the peak of hyperglycemia (1 h after envenoming). The re-
sults demonstrate that Ts venom did not change insulin
levels in BALB/c mice (Fig. 4b). As to the NOD group, a
significant increase of insulin was observed in the enve-
nomed mice. On the other hand, no significant changes
on insulin levels were found in the NOD control group.
Discussion
The venom of T. serrulatus (Ts) is widely studied espe-
cially because of its biologically active compounds
including the neurotoxins, a class of peptides mostly
specific to voltage-gated sodium (Nav) or potassium
(Kv) channels [29]. So far, the actions of Ts neurotoxins
on Nav and Kv channels have demonstrated a gamut of
physiological responses, including the increasing of
plasma glucose levels [14, 15, 30–40]. Although the
mechanism of hyperglycemia induced by scorpions’
venom is not clearly understood, there are studies
demonstrating that it can occur through the excessive
release of catecholamine, increases in glucagon and
cortisol, and alterations in thyroid hormone levels or
insulin secretion [41–43]. Furthermore, an isolated α-
toxin from Ts, denominated Ts5, demonstrated a direct
effect on isolated islets of Langerhans (not provided by
catecholamine’s action), enhancing β-cell membrane
depolarization and significantly potentiating glucose-
induced insulin secretion [43]. Therefore, this pioneer-
ing study aimed to elucidate the effect of hyperglycemia
induced by Ts venom in diabetic individuals, using a
NOD mouse model.
The Ts pooled venom used in the study showed a
protein profile similar to others previous described,
presenting protein masses corresponding to neuro-
toxins specific to sodium (NaTxs) and potassium
(KTxs) channels [27, 44].
The in vivo assays demonstrated that blood glucose
levels significantly increase 1 h after Ts injection
(0.5 mg/kg), independently of the mouse model. Indeed,
the highest glucose level at 1 h after envenoming has
already been described in Wistar rats using the same
dose (0.5 mg/kg) and intraperitoneal (i.p.) injection, and
in BALB/c mice using 1 mg/kg of Ts venom and sub-
cutaneous (s.c.) injection [14, 15]. A peculiar observation
during our experimental design standardization was that
either the highest dose of Ts venom (1 mg/kg) or the
highest glucose basal levels (≥200 mg/dL) cause NOD
mice lethality. Furthermore, the surviving mouse that
presented basal glucose ≥ 200 mg/dL and received
0.5 mg/kg of Ts venom (n = 1) demonstrated a clinical
sequela represented by an ocular disease with partial loss
of vision, probably retinopathy (Additional file 1).
The retina is an insulin-sensitive tissue and excess
glucose or lipids may exert their noxious effects, accel-
erating retinal cell death [45]. NOD mice frequently
present diabetic retinopathy, with histological analysis
showing loss of retinal microvessels and reduced
Fig. 4 Blood glycosylated hemoglobin (HbA1c) percentage (%) and insulin plasma levels from BALB/c and NOD mice injected with Ts venom. Groups
of mice were injected with 0.5 mg/kg of T. serrulatus venom (TsV). a HbA1c % was measured 30 days after challenge. b Insulin was measured 1 h after
challenge. Results are expressed as means ± SD (n = 4), which were analyzed by ANOVA and Tukey’s multiple comparison test (*p < 0.05)
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perfusion of the retina, which result in hypoxia with
evidence of disordered focal proliferation of new ves-
sels [46]. Definitely, diabetic retinopathy is a frequent
cause of blindness developed by diabetic individuals
after macular edema [47]. Nevertheless, the retinop-
athy induced by Ts venom in diabetic mice requires
further investigation.
During the Ts venom-induced glucose kinetic assay,
we also observed a period in which the glucose reached
levels lower than basal glycemia, which was previously
described as a hypoglycemic period [14, 15]. BALB/c
mice reduced glucose levels at 4 h following Ts venom
injection, while NOD demonstrated a prolonged de-
crease of glucose levels at 5 to 6 h following Ts venom
injection. It is known that beta cells of the islets of
Langerhans sense changes in the plasma glucose levels
and adjust the rate of insulin production aiming to
maintain the homeostatic glucose plasma concentration
[48]. Thus, we assume that the production of insulin to
control hyperglycemia induced by such envenoming re-
mains high and, along with a decrease in glycogenolysis
(due to hepatic glycogen depletion), causes a reduction
of glucose levels.
Regarding NOD animals, the delayed hypoglycemia
can be explained by the higher glucose levels required
to be controlled, and the prolonged hypoglycemia
(2 h) by the higher rates of insulin production. In-
deed, a significant increasing of insulin was observed
in NOD animals challenged with Ts venom. Although
the increasing of this hormone in NOD mice seems
peculiar, we assume that their diabetic disease was
not sufficiently advanced to impair the insulin pro-
duction significantly (the decrease of basal insulin of
NOD control animals was not statistically significant
compared to BALB/c control). In this sense, the ani-
mals still present a number of suitable insulin-
producing beta cells in the islets of Langerhans.
According to the literature, the NOD model acquires
insulin deficit after the age of 14 weeks (with high variety
among individuals), that is, before this period, despite pre-
senting high glucose levels, the animals still produce insu-
lin. On the other hand, when these mice become overtly
diabetic, they quickly lose weight and require insulin treat-
ment [49]. The effect of high insulin levels observed in
NOD-envenomed mice is somewhat controversial. This
effect may be beneficial, since insulin treatment in scor-
pion sting victims is known as a metabolic support, which
controls the adverse metabolic response produced by cate-
cholamines and other counter-regulatory hormones [50];
or it could be unfavorable, since the injection of insulin
after Ts envenoming can enhance the venom’s lethality
[15]. Based on the latter, the lethality induced by Ts
sting among diabetic individuals should be higher than
that in healthy humans. In any case, insulin therapy
after Ts envenoming should be further investigated in
diabetic individuals, especially insulin-dependent ones.
On the other hand, BALB/c envenomed group did not
present differences in insulin production compared to
BALB/c control, although hyperinsulinemia has been re-
ported previously during envenoming by the scorpion
Mesobuthus tamulus concanesis and even by T. serrulatus
[15, 42]. However, in the Ts study, the authors used a rat
model and i.p. injection, which may justify such differences.
We also evaluated the glycosylated hemoglobin
(HbA1c) percentage, which is the primary method
recommended before initiating therapy in diabetes pa-
tients [51]. Our results demonstrated that NOD con-
trol animals surely presented a diabetic clinical
condition showing HbA1c higher than 7 % while the
NOD envenomed group displayed a significant eleva-
tion, with levels higher than 8 %. The augmentation
of HbA1c is considered a risk factor for diabetic
neuropathy and retinopathy [52]. This also explains
why we observed only an ocular alteration in the
envenomed group of NOD mice.
Currently, the treatment used for Ts accidents varies
according to the clinical severity, which depends on
the signs and symptoms manifested by the patient.
Mild and moderate cases of Ts envenoming consist
mostly of pain relief through analgesics at the sting
site, orally or parenterally. On the other hand, severe
scorpion envenoming cases require the mandatory use
of the specific antivenom. In Brazil, the available anti-
venoms used for Ts envenoming are the scorpion anti-
venom (SAE or soro antiescorpiônico in Portuguese)
and the arachnid antivenom (SAAr or soro antiaracní-
deo in Portuguese). Their use is also compulsory in
children under 7 years and in adults with previous
health problems (e.g. hypertension and cardiovascular
problems) even if they present mild or moderate clin-
ical manifestations [1, 53]. In this regard, our results
support the hypothesis that diabetic victims present a
higher risk of developing severe envenoming. Therefore,
we also advise consideration of the use of antivenom in
cases of Ts envenoming in diabetic persons ─ a risk
group for Ts envenoming severity.
Conclusion
Our study, for the first time, experimentally demon-
strates that accidents caused by Ts scorpion in diabetic
patients should be always considered a severe case of
envenoming and that greater attention should be given
to these cases. Moreover, as well as the envenomed
NOD animals, these patients can present a higher risk of
death and sequelae. We suggest that glucose, insulin and
HbA1c levels need to be carefully monitored in diabetic
patients.
de Oliveira et al. Journal of Venomous Animals and Toxins including Tropical Diseases  (2016) 22:26 Page 6 of 8
Additional file
Additional file 1: Representative comparison of eyeball of Ts envenomed
and non-envenomed mice. Mice were injected with Ts venom (1 mg/kg). (A)
Envenomed NOD mice with glucose basal level≥ 200 mg/dL, retinopathy
indication. (B) Envenomed BALB/c mice, typical ptosis. (C) BALB/c mice
control (non-envenomed), normal eyeball. (PPTX 81 kb)
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